New drug sequence aims to outsmart resistant breast cancer
NCT ID NCT06533826
First seen Nov 01, 2025 · Last updated Apr 25, 2026 · Updated 26 times
Summary
This study tests whether giving two different antibody drug conjugates (Dato-DXd and T-DXd) one after the other can shrink tumors in people with HER2-negative metastatic breast cancer whose cancer has already progressed after prior antibody drug conjugate therapy. About 357 participants will receive one drug first, then switch to the other if needed. The goal is to see if this sequence improves response rates and delays further progression.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Baylor College of Medicine
RECRUITINGHouston, Texas, 77030, United States
Contact Email: •••••@•••••
Contact
-
Beth Israel Deaconess Medical Center
RECRUITINGBoston, Massachusetts, 02215, United States
Contact Email: •••••@•••••
Contact
-
Dana-Farber Cancer Institute
RECRUITINGBoston, Massachusetts, 02215, United States
Contact Phone: •••-•••-••••
Contact
-
Georgetown University Medical Center
RECRUITINGWashington D.C., District of Columbia, 20007, United States
Contact Email: •••••@•••••
Contact
-
Montefiore Einstein Comprehensive Cancer Center
RECRUITINGThe Bronx, New York, 10461, United States
Contact Email: •••••@•••••
Contact
-
University of Alabama
RECRUITINGBirmingham, Alabama, 35294, United States
Contact Email: •••••@•••••
Contact
-
University of Chicago Medical Center
RECRUITINGChicago, Illinois, 60637, United States
Contact Email: •••••@•••••
Contact
-
University of North Carolina
RECRUITINGChapel Hill, North Carolina, 27599, United States
Contact Email: •••••@•••••
Contact
-
University of San Francisco
RECRUITINGSan Francisco, California, 94158, United States
Contact Email: •••••@•••••
Contact
-
Vanderbilt Cancer Center
RECRUITINGNashville, Tennessee, 37232, United States
Contact
Contact Email: •••••@•••••
-
Yale University Cancer Center
RECRUITINGNew Haven, Connecticut, 06520, United States
Contact Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.